Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms
| Autor: | Frédéric Anselme, Malte Kuniss, Nicolas Badenco, Jian Chen, Christian Meyer, Jean Sylvain Hermida, Rachelle E Kaplon, Cryo-FIRST Investigators, Lukas R.C. Dekker, Fernando Scazzuso, Carlo de Asmundis, Saverio Iacopino, Fabio Di Piazza, Gian-Battista Chierchia, Vedran Velagić, Giuseppe Arena, Douglas L. Packer, Stewart Healey, Nikola Pavlović, H. F. Pitschner |
|---|---|
| Přispěvatelé: | Clinical sciences, Heartrhythmmanagement |
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent medicine.medical_treatment Patient diary Catheter ablation Rhythm control Cryosurgery cryoballoon ablation Young Adult Pharmacotherapy Quality of life Internal medicine Atrial Fibrillation medicine Palpitations Humans Cryoballoon ablation Aged business.industry Atrial fibrillation Middle Aged medicine.disease Antiarrhythmic drugs Treatment Outcome Catheter Ablation Quality of Life medicine.symptom Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents |
| Zdroj: | American Heart Journal |
| ISSN: | 0002-8703 |
| DOI: | 10.1016/j.ahj.2021.08.007 |
| Popis: | BACKGROUND: Cryoballoon ablation (CBA) as a first-line rhythm control strategy is superior to antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) recurrence; the impact of first-line CBA on quality of life (QoL) and symptoms has not been well characterized. METHODS: Patients aged 18 to 75 with symptomatic paroxysmal AF naïve to rhythm control therapy were randomized (1:1) to CBA (Arctic Front Advance, Medtronic) or AAD (Class I or III). Symptoms and QoL were assessed at baseline, 1, 3, 6, 9, and 12 months using the EHRA classification and Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and SF-36v2 questionnaires. Symptomatic palpitations were evaluated via patient diary. RESULTS: Overall, 107 patients were randomized to CBA and 111 to AAD; crossovers occurred in 9%. Larger improvements in the AFEQT summary, subscale and treatment satisfaction scores were observed at 12 months with CBA vs AAD (all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect